Overview

* Emergent Q2 revenue of $140.9 mln missed analyst expectations, exceeded Co's guidance by $21 mln

* Adjusted EBITDA rose 382% to $28.5 mln, beating analyst estimates

* Company raised low end/midpoint of full-year 2025 profitability guidance

Outlook

* Emergent raises full-year 2025 revenue guidance to $765-$835 mln

* Company revises 2025 net income forecast to $40-$65 mln

* Company anticipates full-year 2025 adjusted EBITDA of $175-$200 mln

Result Drivers

* NALAXONE SALES DECLINE - Revenues from NARCAN Nasal Spray fell 44% due to unfavorable price and volume mix

* ANTHRAX MCM SALES TIMING - Anthrax MCM revenues decreased 70% due to timing of sales related to CYFENDUS

* SMALLPOX MCM SALES INCREASE - Smallpox MCM revenues rose 127% driven by higher VIGIV CNJ-016 sales

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $140.90 $146.40

Revenue mln mln (3

Analysts

)

Q2 $0.16

Adjusted

EPS

Q2 Beat $8.60 -$27.60

Adjusted mln mln (2

Net Analysts

Income )

Q2 Net -$12 mln

Income

Q2 Beat $28.50 -$10.30

Adjusted mln mln (1

EBITDA Analyst)

Q2 Gross 36.0%

Margin

Q2 49.0%

Adjusted

Gross

Margin

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Emergent BioSolutions Inc ( EBS ) is $13.50, about 54.8% above its August 5 closing price of $6.10

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)